TY - JOUR
T1 - Initial chemotherapy followed by surgical cytoreduction for the treatment of stage III/IV epithelial ovarian cancer
AU - Everett, Elise N.
AU - French, Amy E.
AU - Stone, Rebecca L.
AU - Pastore, Lisa M.
AU - Jazaeri, Amir A.
AU - Andersen, Willie A.
AU - Taylor, Peyton T.
PY - 2006/8
Y1 - 2006/8
N2 - Objective: The purpose of this study was to evaluate differences in morbidity, progression-free interval, and survival in women with advanced epithelial ovarian cancer treated with initial chemotherapy versus initial surgery. Study design: All women with epithelial ovarian cancer who were treated surgically at our hospital between January 1, 1995, and January 1, 2003, were eligible; the cases of 200 patients met the criteria and underwent retrospective chart review. Results: Ninety-eight patients (49%) had initial chemotherapy, and 102 patients (51%) had initial surgery. Patients who received initial chemotherapy were more likely to have stage IV disease (initial chemotherapy, 27%, vs initial surgery, 8%; P = .042) and grade 3 disease (initial chemotherapy, 73%, vs initial surgery, 61%; P = .025). Optimal cytoreduction was achieved more often in patients who received initial chemotherapy (initial chemotherapy, 86%, vs initial surgery, 54%; P < .001). Only optimal cytoreduction (P = .022), and not treatment choice (P = .089), had an impact on median survival. Conclusion: Initial chemotherapy is a reasonable alternative to initial surgery for the treatment of selected patients with advanced epithelial ovarian cancer.
AB - Objective: The purpose of this study was to evaluate differences in morbidity, progression-free interval, and survival in women with advanced epithelial ovarian cancer treated with initial chemotherapy versus initial surgery. Study design: All women with epithelial ovarian cancer who were treated surgically at our hospital between January 1, 1995, and January 1, 2003, were eligible; the cases of 200 patients met the criteria and underwent retrospective chart review. Results: Ninety-eight patients (49%) had initial chemotherapy, and 102 patients (51%) had initial surgery. Patients who received initial chemotherapy were more likely to have stage IV disease (initial chemotherapy, 27%, vs initial surgery, 8%; P = .042) and grade 3 disease (initial chemotherapy, 73%, vs initial surgery, 61%; P = .025). Optimal cytoreduction was achieved more often in patients who received initial chemotherapy (initial chemotherapy, 86%, vs initial surgery, 54%; P < .001). Only optimal cytoreduction (P = .022), and not treatment choice (P = .089), had an impact on median survival. Conclusion: Initial chemotherapy is a reasonable alternative to initial surgery for the treatment of selected patients with advanced epithelial ovarian cancer.
KW - Cytoreduction
KW - Neoadjuvant chemotherapy
KW - Ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=33746481520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746481520&partnerID=8YFLogxK
U2 - 10.1016/j.ajog.2006.03.075
DO - 10.1016/j.ajog.2006.03.075
M3 - Article
C2 - 16890558
AN - SCOPUS:33746481520
SN - 0002-9378
VL - 195
SP - 568
EP - 574
JO - American journal of obstetrics and gynecology
JF - American journal of obstetrics and gynecology
IS - 2
ER -